About

An independent resource on ibogaine research and multiple sclerosis.

Lumenbra helps people examine the limited evidence, unanswered questions, and known risks surrounding ibogaine for multiple sclerosis. Our work is evidence-first and organized to make uncertainty explicit so readers can weigh claims responsibly.

For context about where this project sits online, our presentation complements other informational sites such as the treatment registry hosted at the ibogaine treatment resource, which we monitor when cataloging available case reports and program descriptions.

Our editorial approach

We summarize research and primary sources with strict separation between what is published and what is interpretation. We prioritize registries, peer-reviewed literature, and official guidance when available, and we flag when evidence consists solely of case reports or small observational series. For general standards on evidence grading and clinical research interpretation, readers can consult guidelines like those from the National Library of Medicine's PubMed resources at PubMed Central.

What we cover

Content is organized by topic area: summaries of published studies, assessments of methodological limits, safety considerations, and plain-language explanations of uncertainty. We surface where contradictory findings exist and where data are sparse so readers understand both claims and gaps. The site also links from conceptual pieces to concise research summaries and to a services index for readers seeking more context about available programs at other organizations.

How information is sourced and vetted

Our editors compile primary research (journal articles, registries, and trial reports) and corroborate factual claims against authoritative sources. When citing historical or regulatory context we rely on recognized references — for example, broad clinical trial guidance from the U.S. National Institutes of Health at NIH and general overviews such as established encyclopedic entries like the ibogaine page on Wikipedia for non-specialist context. We avoid translating preliminary findings into treatment recommendations.

Standards we apply

  • Prefer peer-reviewed sources and clinical trial registries over anecdote.
  • Note conflicts of interest and methodological limitations plainly.
  • Use neutral, plain language so conclusions are clear but tentative where appropriate.

Who this is for

This resource is aimed at people affected by multiple sclerosis, their supporters, and readers trying to assess claims about ibogaine with care. For readers who want an overview of the site's scope and services we offer guidance and context — including short descriptions of how third‑party programs are described — and we link to a concise listing under our services index where readers can find topic-aligned summaries and external program descriptions.

Editorial principles

  • Scientific restraint — we do not overstate what limited evidence can show.
  • Plain language — complex findings are presented clearly and without jargon.
  • Safety awareness — potential risks are highlighted alongside any reported outcomes.
  • Independence — we avoid affiliation claims and disclose limitations of our reporting.

FAQ

Does Lumenbra provide clinical treatment or referrals?

No. We are an information resource and do not provide clinical care or act as a licensed referral service; readers seeking care should consult licensed medical professionals or official registries.

How often is the site updated?

We update summaries when new peer-reviewed studies or significant registry reports are published. We monitor public registries and scientific literature rather than individual testimonials, and when a new study appears we document its date and source so readers can see how recent the evidence is.

Where do you get your data?

Primary sources include clinical and registry reports, indexed literature, and official guidance documents; for clinical trial metadata we reference trial registries and curated repositories rather than anecdotal sources. For general methodological standards see the CONSORT guidelines and trial registration practices described by institutions like the World Health Organization.

How can I contact Lumenbra?

Use the Contact link in the site navigation to reach our editorial team through the published contact page.

For a broad registry of ibogaine programs we track, see the treatment directory hosted at the ibogaine treatment resource.